A BILL 
To authorize the Patient-Centered Outcomes Research Insti-
tute to fund research of the symptoms of COVID–19, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘COVID–19 Long 
4
Haulers Act’’. 
5
02:39 Jan 05, 2021
H9027
2 
•HR 9027 IH
SEC. 2. AUTHORIZATION TO FUND RESEARCH OF THE 
1
LONG-TERM SYMPTOMS OF COVID–19 BY THE 
2
PATIENT-CENTERED OUTCOMES RESEARCH 
3
INSTITUTE. 
4
(a) IN GENERAL.—The Patient-Centered Outcomes 
5
Research Institute under section 1181(b) of the Social Se-
6
curity Act (42 U.S.C. 1320e(b)) shall fund research de-
7
scribed in subsection (b). 
8
(b) RESEARCH DESCRIBED.—For purposes of sub-
9
section (a), research described in this subsection shall in-
10
clude— 
11
(1) prior to creating a patient registry described 
12
in paragraph (2), survey existing patient registries 
13
that include individuals experiencing post-acute 
14
sequelae of COVID–19; 
15
(2) creating a patient registry for those with 
16
COVID–19 with information that— 
17
(A) contains the— 
18
(i) symptoms that arise while an indi-
19
vidual is actively infected with COVID–19 
20
and that resolve while such individual is 
21
actively infected; 
22
(ii) symptoms that arise while an indi-
23
vidual is actively infected with COVID–19 
24
and that extend after the infection has re-
25
solved; 
26
02:39 Jan 05, 2021
H9027
3 
•HR 9027 IH
(iii) symptoms that arise after an in-
1
dividual is actively infected with COVID– 
2
19 and that endure and that the clinician 
3
of such individual has reason to suspect 
4
were related to the COVID–19 diagnosis; 
5
(iv) symptoms that arise in an indi-
6
vidual that may be related to COVID–19 
7
but a diagnosis of COVID–19 was not ob-
8
tained and cannot be identified due to a 
9
lack of antibodies; 
10
(v) treatments of individuals after pri-
11
mary diagnosis to COVID–19 and the ef-
12
fectiveness of such treatments disaggre-
13
gated by age, gender, and race or eth-
14
nicity; and 
15
(vi) any other relevant questions or 
16
issues related to individuals who experience 
17
a diagnosis of, treatment for, and manage-
18
ment of care with COVID–19; 
19
(B) synthesizes information relating to in-
20
dividuals experiencing post-acute sequelae of 
21
COVID–19 identified from the survey described 
22
in paragraph (1) and information under the pa-
23
tient registry described in paragraph (2); and 
24
02:39 Jan 05, 2021
H9027
4 
•HR 9027 IH
(3) outreach and inclusion (as appropriate) in-
1
dividuals from communities with traditional health 
2
disparities and inequities. 
3
(c) REPORT.—Not later than 1 year after the estab-
4
lishment of the synthesized patient registry described in 
5
subsection (a)(2), and annually thereafter, the Patient- 
6
Centered Outcomes Research Institute shall submit data, 
7
findings, and information with respect to the status of the 
8
patient registry (including progress, barriers, and issues) 
9
to Congress and the President. 
10
(d) AUTHORIZATION OF APPROPRIATIONS.—There is 
11
hereby authorized $30,000,000 for fiscal year 2021 to 
12
carry out this section, which shall remain available until 
13
expended. 
14
SEC. 3. AUTHORIZATION OF APPROPRIATIONS FOR RE-
15
SEARCH WITH RESPECT TO INDIVIDUALS EX-
16
PERIENCING 
SEQUELAE 
OF 
17
COVID–19 BY THE NIH. 
18
(a) IN GENERAL.—The Director of the National In-
19
stitutes of Health conduct research with respect to individ-
20
uals experiencing post-acute sequelae of COVID–19. 
21
(b) AUTHORIZATION OF APPROPRIATIONS.—There is 
22
hereby authorized $100,000,000 for fiscal year 2021 to 
23
02:39 Jan 05, 2021
H9027
5 
•HR 9027 IH
carry out this section, which shall remain available until 
1
expended. 
2
Æ 
02:39 Jan 05, 2021
H9027
